Enveric Biosciences Inc (ENVB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Enveric Biosciences Inc stock (ENVB) is currently trading at $1.97. Enveric Biosciences Inc PS ratio (Price-to-Sales) is 0.08. Analyst consensus price target for ENVB is $10.00. WallStSmart rates ENVB as Sell.
- ENVB PE ratio analysis and historical PE chart
- ENVB PS ratio (Price-to-Sales) history and trend
- ENVB intrinsic value — DCF, Graham Number, EPV models
- ENVB stock price prediction 2025 2026 2027 2028 2029 2030
- ENVB fair value vs current price
- ENVB insider transactions and insider buying
- Is ENVB undervalued or overvalued?
- Enveric Biosciences Inc financial analysis — revenue, earnings, cash flow
- ENVB Piotroski F-Score and Altman Z-Score
- ENVB analyst price target and Smart Rating
Enveric Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Enveric Biosciences Inc (ENVB) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Enveric Biosciences Inc (ENVB) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Enveric Biosciences Inc (ENVB) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -7.30%, a shrinking business
Very low institutional interest at 6.94%
Micro-cap company with very limited liquidity and high volatility
Enveric Biosciences Inc (ENVB) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.08), Price/Book (0.82) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Institutional Own.. Growth concerns include Revenue Growth at -7.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -262.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -262.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -7.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ENVB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ENVB's Price-to-Sales ratio of 0.08x trades 58% above its historical average of 0.05x (77th percentile), historically expensive. The current valuation is 62% below its historical high of 0.21x set in Mar 2016, and Infinity% above its historical low of 0x in Oct 2019. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Enveric Biosciences Inc (ENVB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Enveric Biosciences Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 35M with 7% decline year-over-year.
Key Findings
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Enveric Biosciences Inc.
Bottom Line
Enveric Biosciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:02:16 AM
About Enveric Biosciences Inc(ENVB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. The company is headquartered in Naples, Florida.